

ForPatients

by Roche

Breast Cancer HER-2 Positive Breast Cancer HER2-Positive Breast Cancer

A study to investigate the effectiveness of trastuzumab emtansine compared with trastuzumab in a type of breast cancer (called HER2 positive breast cancer) for patients who still have signs of tumours after receiving previous treatment and undergoing surgery (KATHERINE)

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Trial Status

Active, not recruiting

Trial Runs In

28 Countries

Trial Identifier

NCT01772472 2012-002018-37
BO27938

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT01772472 2012-002018-37 BO27938

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

≥ 18 Years

Healthy Volunteers

No